Priming of cancer cells with low dose naltrexone
US12144807B2 · kind B2 · utility
0Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 18, 2021 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Jul 21, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides methods of treating a tumor/cancer by administering naltrexone or an analogue thereof, followed by a recovery phase, and then administering a small molecule signaling inhibitor such as PI3-kinase inhibitors, AKT inhibitors, taxanes, antimetabolites, alkylating agents and/or cell cycle inhibitors. The disclosure also provides diagnostic methods for assessing a therapeutic response to the methods of treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.